When was Sutro Biopharma founded?

Sutro Biopharma was founded in 2003 and raised its 1st funding round 2 years after it was founded.

Where is Sutro Biopharma located?

Sutro Biopharma is headquartered in United States. It is registered at South San Francisco,California.

How many employees does Sutro Biopharma have?

As of Mar 31, 2026, the latest employee count at Sutro Biopharma is 223.

Is Sutro Biopharma a funded company?

Sutro Biopharma is a funded company, having raised a total of $175M across 11 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 01, 2005.

When was the latest funding round of Sutro Biopharma?

Sutro Biopharma's latest funding was a $***** Series E round on Jul 26, 2018, with participation from 13 investors.

What is the annual revenue of Sutro Biopharma?

Annual revenue of Sutro Biopharma is $102M as on Dec 31, 2025.

Where does Sutro Biopharma rank among its competitors?

Sutro Biopharma ranks 28th amongst 5068 active competitors, of which 1525 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was C4 Therapeutics, which secured $25M in Jan, 2024.

Who are the top competitors of Sutro Biopharma?

Sutro Biopharma's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Kite Pharma. Among them, C4 Therapeutics secured the most recent funding round in January, 2024.

Sutro Biopharma - 2026 Company Profile, Team, Funding, Competitors & Financials

Sutro Biopharma is a public company based in United States, founded in 2003 by Diego Fonstad. It operates as a Developer of antibody-based therapeutics for cancer therapy. Sutro Biopharma has raised $175M in funding from investors like Skyline Ventures, Alta Partners and SV Health Investors. The company has 5068 active competitors, including 1525 funded and 1090 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Kite Pharma.

Company Details

Developer of antibody-based therapeutics for cancer therapy. The company uses cell-free protein synthesis platform XpressCF technology led to the discovery of STRO-001 and STRO-002, for B-cell malignancies, ovarian and endometrial cancers.

Website: www.sutrobio.com/
Social
Email ID: *****@sutrobio.com
Phone Number: +1 **********
Registered Address: South San Francisco,California

Key Metrics

Founded Year

2003

Location

United States

Stage

Public

Total Funding

$175M in 11 rounds

Latest Funding Round

Series E, Jul 26, 2018, $*****

Investors

Skyline Ventures & 18 more

Ranked

28^th among 5068 active competitors

Annual Revenue

$102M as on Dec 31, 2025

Employee Count

223 as on Mar 31, 2026

Similar Companies

Jazz Pharmaceuticals & 5595 more

Exit Details

Public

View Sutro Biopharma's full profile

Sutro Biopharma is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Sutro Biopharma, Inc. CIN: 470926186 , United States, Active	Dec 31, 1999	$102M (As on Dec 31, 2025)	340 (As on Dec 31, 2024)	-

Sutro Biopharma got listed on Sep 27, 2018.

Click here to take a look at Sutro Biopharma's IPO in detail

Sutro Biopharma has raised a total funding of $175M over 11 rounds. Its first funding round was on Sep 01, 2005. Its latest funding round was a Series E round on Jul 26, 2018 for $*****. 13 investors participated in its latest round. Sutro Biopharma has 19 institutional investors.

Here is the list of recent funding rounds of Sutro Biopharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 26, 2018	9336068	Series E	1859267	8627102	1225437	2701588
Dec 11, 2013	4019314	Series D	8737980	3950115	1237775	Amgen Business Development
May 08, 2012	6058744	Series C	6561885	8963067	Skyline Ventures	Lilly Ventures & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Sutro Biopharma's funding rounds and investors

The founders of Sutro Biopharma is Diego Fonstad.

Here are the details of Sutro Biopharma's key team members:

Diego Fonstad: Co-Founder of Sutro Biopharma.

View details of Sutro Biopharma's Founder profiles and Board Members

Sutro Biopharma's employee count trend

Sutro Biopharma has 223 employees as of Mar 26. Here is Sutro Biopharma's employee count trend over the years:

Employee count trend for Sutro Biopharma

Uncover Sutro Biopharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Sutro Biopharma include Jazz Pharmaceuticals, Sana Biotechnology and Kite Pharma. Here is the list of Top 10 competitors of Sutro Biopharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	RA Capital Management, BB Biotech & 14 others	74/100
6th	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Tamburi Investment Partners, Vivo Capital ... & 4 others	73/100
7th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
8th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
9th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Kaccelerator & 7 others	72/100
10th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
28th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Citadel, Amgen Business Development & 17 others	72/100